
|Videos|August 11, 2021
Bausch + Lomb: clinical trial, pipeline updates for 2021
Author(s)Sheryl Stevenson, Alex Delaney-Gesing
Advertisement
Yolande Barnard, vice president and general manager of U.S. Pharmaceuticals at Bausch + Lomb, shares an update on the company's latest treatment for patients with DED associated with MGD as well as an investigational drug for the treatment of macular edema associated with uveitis.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Midyear cataract check-in: What 2026 has brought to the OR and beyond
2
Recognizing biomarkers of Alzheimer Disease using OCTA
3
Tinlarebant NDA submission completed for Stargardt disease type 1, targeting first approved therapy
4
Next-Generation Anti-VEGF Therapies in Retinal Vascular Diseases
5




















